Xtant Medical Holdings, Inc. revised earnings guidance for the year 2023. For the year, the company raises its expectation for full year 2023 revenue to $88 million to $91 million, up from the Company?s prior guidance of $75 million to $77 million. The revised guidance range represents annual revenue growth of approximately 52% to 57% compared to full year 2022 revenue, and includes contributions from the Surgalign transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8103 USD | +0.04% | -4.67% | -28.29% |
Apr. 30 | Xtant Medical Holdings, Inc. Announces Launch of SimpliGraft and SimpliMax for Chronic and Acute Wounds | CI |
Apr. 01 | Xtant Medical Files $150 Million Mixed Shelf; Shares Fall | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.29% | 106M | |
+10.39% | 126B | |
+2.52% | 8.97B | |
+38.96% | 5.56B | |
-17.50% | 4.99B | |
+8.36% | 3.44B | |
-8.84% | 2.8B | |
-7.52% | 2.18B | |
-3.00% | 2.16B | |
-21.88% | 1.82B |
- Stock Market
- Equities
- XTNT Stock
- News Xtant Medical Holdings, Inc.
- Xtant Medical Holdings, Inc. Revises Earnings Guidance for the Year 2023